期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
胃癌耐药相关抗体MGr1筛选文库获得的基因MGr1-Ag1在胃癌组织中表达的研究 被引量:3
1
作者 尹芳 时永全 +4 位作者 陈彩平 乔泰东 陈宝军 苗继延 樊代明 《世界华人消化杂志》 CAS 2003年第1期18-21,共4页
目的:为研究肿瘤的多药耐药现象,应用胃癌耐药相关的单克隆抗体MGr1筛选肿瘤耐药细胞表达文库获得的一个稳定阳性克隆的cDNA片段MGr1-Ag1,检测MGr1-Ag1在胃癌组织中的分布及表达水平.方法:利用原位杂交技术,对MGr1-Ag1mRNA在胃癌组织中... 目的:为研究肿瘤的多药耐药现象,应用胃癌耐药相关的单克隆抗体MGr1筛选肿瘤耐药细胞表达文库获得的一个稳定阳性克隆的cDNA片段MGr1-Ag1,检测MGr1-Ag1在胃癌组织中的分布及表达水平.方法:利用原位杂交技术,对MGr1-Ag1mRNA在胃癌组织中的分布进行了检测,以了解其在胃癌中的表达情况及意义.结果:MGr1-Ag1mRNA定位在胃腺体细胞的胞质中,为蓝色小颗粒,呈弥漫性分布.MGr1-Ag1mRNA在SGC7901/VCR阳性信号明显高于SGC7901,胃癌与癌旁组织相比,MGr1-Ag1mRNA的阳性表达率均有显著差异(P<0.05).MGr1-Ag1mRNA在胃癌(50.00%)、癌旁组织(71.42%)、高分化腺癌(68.75%)和中分化腺癌组织(57.14%)中的阳性表达率无显著差别,但高分化组和中分化组都与低分化腺癌组织(10.00%)差别显著(P<0.05).此外,MGr1-Ag1mRNA还分布于小肠及大肠腺体内,因例数偏少,未做统计.结论:MGr1-Ag1与胃癌的分化程度有关,随着组织的分化程度增高,MGr1-Ag1mRNA的阳性表达率增加. 展开更多
关键词 胃癌 相关抗体 MGr1 筛选 文库 基因 MGr1Ag1
下载PDF
CD59在肿瘤发生发展及抗体治疗中的作用
2
作者 欧阳倩雯 胡维国 +1 位作者 罗荣城 邵志敏 《分子影像学杂志》 2013年第1期36-39,共4页
CD59是唯一作用于补体系统激活终末阶段的补体膜调控抑制性蛋白,通过与补体攻膜复合物(MAC)装配过程中的C8α和/或C9结合、从而阻止C9多聚化,最终抑制MAC的形成,调节补体活性。大量研究表明,补体依赖的细胞毒作用(CDC)是肿瘤临床治疗抗... CD59是唯一作用于补体系统激活终末阶段的补体膜调控抑制性蛋白,通过与补体攻膜复合物(MAC)装配过程中的C8α和/或C9结合、从而阻止C9多聚化,最终抑制MAC的形成,调节补体活性。大量研究表明,补体依赖的细胞毒作用(CDC)是肿瘤临床治疗抗体(如美罗华)重要的抗肿瘤杀伤机制,而CDC效应的下降是肿瘤对抗体治疗耐药的重要原因之一。肿瘤细胞膜表面高表达的CD59在此过程中发挥了重要的作用;同时,CD59与肿瘤细胞凋亡、肿瘤干细胞、肿瘤转移和肿瘤血管生成等密切相关,这提示CD59有可能成为潜在的肿瘤治疗靶点之一。现对目前关于CD59在肿瘤中的研究进展进行综述,并探讨CD59在肿瘤发生发展与抗体治疗中的作用及应对策略。 展开更多
关键词 补体系统 CD59 肿瘤发生 抗体耐药
下载PDF
靶向人表皮生长因子受体的抗体药物研究进展 被引量:1
3
作者 杨赟 彭晓芸 +3 位作者 李彦涛 郭怀祖 侯盛 王皓 《现代免疫学》 CAS CSCD 北大核心 2015年第2期172-174,144,共4页
人表皮生长因子受体(EGFR)是肿瘤治疗,尤其是肿瘤的靶向治疗中重要的靶标。以其为靶点开发的抗体药物已经广泛用于癌症的治疗,尤其是转移性结直肠癌、头颈部癌症等的治疗。本文综述了靶向EGFR的抗体药物相关研究背景及最新研究进展,将... 人表皮生长因子受体(EGFR)是肿瘤治疗,尤其是肿瘤的靶向治疗中重要的靶标。以其为靶点开发的抗体药物已经广泛用于癌症的治疗,尤其是转移性结直肠癌、头颈部癌症等的治疗。本文综述了靶向EGFR的抗体药物相关研究背景及最新研究进展,将为开发针对该靶点新型抗体提供参考。 展开更多
关键词 EGFR 靶向治疗 皮肤毒性 抗体耐药 新型抗体
原文传递
Preparation of anti-resistant stealthy liposomes by incorporating vincristine with quinacrine and the pharmacokinetics in Sprague-Dawley rats
4
作者 梁公文 吕万良 +7 位作者 吴瑨威 赵继会 李婷 张宇腾 张华 王坚成 张烜 张强 《Journal of Chinese Pharmaceutical Sciences》 CAS 2007年第2期105-111,共7页
Aim The objectives of the present study were to prepare stealthy vincristine plus quinacrine liposomes and evaluate the pharmacokinetics in Sprague-Dawley rats. Methods Anti-resistant stealthy liposomes were prepared ... Aim The objectives of the present study were to prepare stealthy vincristine plus quinacrine liposomes and evaluate the pharmacokinetics in Sprague-Dawley rats. Methods Anti-resistant stealthy liposomes were prepared by incorporating vincristine with quinacrine together using the ammonium sulfate gradient loading procedure. For the pharmacokinetic study, Sprague-Dawley rats were divided into two groups: each rat in the Group Ⅰwas administered intravenously via tail vein as stealthy liposomal vincristine plus quinacrine, and the Group Ⅱ similarly given as a mixture solution of free vincristine plus free quinacrine. The concentrations of vincristine and quinacrine in plasma were measured by HPLC with diode array detection and fluorescence detection, respectively. Results The mean particle size of stealthy liposomes was 135.9 ±7.1 nm and the encapsulation efficiencies of stealthy liposomes were 〉 90% for vincristine, and 〉 85% for quinacrine, respectively. Administered as the stealthy vincristine plus quinacrine liposomes, the plasma exposures of both vincristine and quinacrine were significantly extended, and the mean concentrations of both vincristine and quinacrine were significantly higher compared to those given as the mixture solution of free vincristine plus free quinacrine. The Cmax, t1/2, AUC0-24 h values of vincristine for stealthy liposomal group were significantly increased, but the total clearance Cl values decreased, as compared to those of free drug group, respectively. Similarly, the Cmax, t1/2 and AUC0-24 h values of quinacrine for the stealthy liposomal group were significantly increased, but the total clearance C1 values decreased, as compared to those of free quinacrine. Conclusion The anti-resistant stealthy liposomes are successfully prepared by incorporating vincristine with quinacrine, and the liposomes extend significantly the duration in blood circulation and improve evidently the plasma concentrations of both vincristine and quinacrine. 展开更多
关键词 Stealthy liposomal vincristine plus quinacrine HPLC PHARMACOKINETICS
下载PDF
Protein photocrosslinking reveals dimer of dimers formation on MarR protein in Escherichia coli 被引量:1
5
作者 CHEN Xing HAO ZiYang CHEN Peng R. 《Science China Chemistry》 SCIE EI CAS 2012年第1期106-111,共6页
The multiple antibiotic resistance regulatory protein(MarR) binds to two promoter sites on the marO operator in Escherichia coli.Our study showed that more than one MarR dimer proteins bound to either of its two promo... The multiple antibiotic resistance regulatory protein(MarR) binds to two promoter sites on the marO operator in Escherichia coli.Our study showed that more than one MarR dimer proteins bound to either of its two promoter sites(Site I and Site II),suggesting that MarR might form higher complexes than homodimers when bound to DNA inside E.coli cells.To further verify this hypothesis,we site-specifically incorporated a photocrosslinking probe at the interface between two MarR dimer proteins.Photolysis in living E.coli cells revealed a covalent linkage between the two interdimer subunits of MarR,suggesting that MarR forms dimer of dimers in vivo. 展开更多
关键词 MarR protein antibiotic resistance protein photocrosslinking DNA binding site DIMERIZATION
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部